Theralase Technologies (TSXV:TLT) FCF Margin % : -345.60% (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Theralase Technologies's Free Cash Flow for the three months ended in Dec. 2023 was C$-1.26 Mil. Theralase Technologies's Revenue for the three months ended in Dec. 2023 was C$0.36 Mil. Therefore, Theralase Technologies's FCF Margin % for the quarter that ended in Dec. 2023 was -345.60%.

As of today, Theralase Technologies's current FCF Yield % is -6.62%.

The historical rank and industry rank for Theralase Technologies's FCF Margin % or its related term are showing as below:

TSXV:TLT' s FCF Margin % Range Over the Past 10 Years
Min: -736.41 Med: -328.1 Max: -77.85
Current: -279.23

During the past 13 years, the highest FCF Margin % of Theralase Technologies was -77.85%. The lowest was -736.41%. And the median was -328.10%.

TSXV:TLT's FCF Margin % is ranked worse than
85.28% of 829 companies
in the Medical Devices & Instruments industry
Industry Median: -7.14 vs TSXV:TLT: -279.23

Theralase Technologies FCF Margin % Historical Data

The historical data trend for Theralase Technologies's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies FCF Margin % Chart

Theralase Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-736.41

-496.34

-528.94

-454.17

-384.11

Theralase Technologies Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-567.82	-348.16	-541.55	-	-345.60

Competitive Comparison of Theralase Technologies's FCF Margin %

For the Medical Devices subindustry, Theralase Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's FCF Margin % falls into.

Theralase Technologies FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Theralase Technologies's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-4.11	/	1.07
	=	-384.11 %

Theralase Technologies's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-1.258	/	0.364
	=	-345.60 %

Theralase Technologies FCF Margin % Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (TSXV:TLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

TLTFF:USA

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

Executives

Matthew Thomas Perraton

Director